U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06892431) titled 'JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer' on March 21.
Brief Summary: This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Recurrent or Metastatic Nasopharyngeal Cancer
Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
Intervention:
DRU...